The NF-κB pathway is downstream of the PI3K/AKT signaling pathway, acting as a master regulator of inflammatory responses, and its abnormal activation is a key pathogenic factor for the development of NAFLD/NASH [36,37]. Here, NFKB1 is linked to metabolic dysfunction-associated steatotic liver disease.